SSA
DFTX

Schonfeld Strategic Advisors’s Definium Therapeutics DFTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$197K Sell
10,412
-20,044
-66% -$340K ﹤0.01% 1754
2025
Q4 		$408K Sell
30,456
-5,054
-14% -$62.5K ﹤0.01% 1471
2025
Q3 		$419K Buy
+35,510
New +$331K ﹤0.01% 1734
2023
Q1 		– Sell
-10,400
Closed -$22.9K – 2422
2022
Q4 		$22.9K Buy
+10,400
New +$28.9K ﹤0.01% 2317

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Schonfeld Strategic Advisors's DFTX Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its Definium Therapeutics (DFTX) stake by 66% in Q1 2026, selling an estimated $340K and leaving 10,412 shares worth $197K. The position accounts for ﹤0.01% of the portfolio, ranked #1754.

Schonfeld Strategic Advisors first reported a position in DFTX in Q4 2022 and has held it in 4 quarters since. The position peaked at $419K in Q3 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Schonfeld Strategic Advisors held 10,412 shares of Definium Therapeutics worth $197K as of Q1 2026.
  • Schonfeld Strategic Advisors sold 20,044 Definium Therapeutics shares in Q1 2026, an estimated $340K.
  • Definium Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1754 holding.
  • Schonfeld Strategic Advisors first reported a position in Definium Therapeutics in Q4 2022 and has held it in 4 quarters since.
  • Schonfeld Strategic Advisors's Definium Therapeutics position peaked at $419K in Q3 2025.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.